Location
Headquarters: Basel, Basel-Stadt, Switzerland, Europe
Region: Basel-Stadt
Country: CH
Continent: Europe
About
Lonza is a leading contract development and manufacturing organization focused on the healthcare industry. Founded in Switzerland in 1897, it operates globally with about 19,000 employees across five continents and offers integrated biologics, small molecule, specialized modalities, and regulatory services to help pharmaceutical and biotech customers bring therapies to market. The company positions itself as a pioneer in the CDMO space with capabilities spanning mammalian biologics, small molecules, cell and gene therapy, and related manufacturing and development services. Lonza serves customers worldwide, delivering life-enhancing and life-saving treatments across diverse therapeutic areas.
Lonza Group AG is a global contract development and manufacturing organization serving the pharmaceutical and biotech industries. The company provides integrated services for biologics, small molecules, cell and gene therapies, and nutrition ingredients. Its customers include drug developers seeking support from preclinical research through commercial production.
Lonza Group AG.
1897
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
874000000
over-1b
ipo
LONN
six
Investors
Founders
Alfons Ehinger
Leadership
James Lugo — Head, Ingredient R&D for Consumer Health & Nutrition Business Unit
Alice Harrison — Global Technical Director
Maria Karatsa-Dodgson — Lead Scientist
Janet Yancey-Wrona — Director, Marketing Testing Solutions
Jean Aucamp — Downstream processing Team Lead
Uwe Gottschalk — Chief Scientific Officer
Dan Mirica — Head of Global Logistics
Technology Stack
Products
Integrated Biologics: End-to-end development and manufacturing services for mammalian biologics, including development, manufacturing, and licensing technologies.
Advanced Synthesis: Manufacturing and development of small molecules, highly potent active pharmaceutical ingredients (HPAPIs), and bioconjugates to support drug development.
Specialized Modalities: Development and manufacturing services for emerging modalities such as mRNA, cell and gene therapies, and microbial technologies.
Capsules & Health Ingredients: Production of capsules and health-related ingredients for pharmaceutical and nutraceutical applications.
Regulatory Affairs Services: Regulatory support services including CMC strategy, dossier preparation, and interaction with global health authorities for drug development and approval.
Funding rounds
Post Ipo Debt · $444.8M · (2023-11-06)
IPO · (2020-12-07)